← Home / Century Therapeutics, Inc. (IPSC)
Stock Analysis

Century Therapeutics, Inc. (IPSC)

IPSC
IPSC · Healthcare • Biotechnology
2.13 -1.84%
Track IPSC in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IPSC price is:
52W Range Position
67%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-26 23:22 UTC
WOI Investment Thesis
Mixed
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Weak / Negative / Pressured / Strong
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
2.08
↗
Break Above
No reliable confirmation level is currently available.
Not available
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
12
●
Financial Results
HIGH
IPSC reports financial results
Item 7.01 Regulation FD Disclosure On August 12, 2026, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
8-K Filing • SEC EDGAR
JUN
16
●
Management / Board
MEDIUM
IPSC board and management update
false 0001850119 0001850119 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju...
8-K Filing • SEC EDGAR
MAY
13
●
Financial Results
HIGH
Century Therapeutics Reports First Quarter Financial Results
and Business Updates · CNTY - 813, Century’s type 1 diabetes iPSC-derived islet therapy with functional - cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 · Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY...
8-K Filing • SEC EDGAR
What's Driving IPSC?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is weak. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
⚠️ Key risk remains
losing 2.08 would weaken the current structure.
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
53.7
Price Chart
IPSC — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-25
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$383.9M
Company size
EV
$302.8M
Debt-adjusted value
P/S
3.5
Low sales multiple
P/B
1.6
Low book multiple
EV/Sales
3.1
Low sales multiple
P/FCF
-7.6
Not meaningful
FCF Yield
-13.13%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
109.16M
↘ Weak
📈 Net Income
-34.55M
↘ Negative
🧮 EPS (Basic)
-0.17
↘ Negative
Century Therapeutics, Inc.
Healthcare • Biotechnology
You Might Also Like